Bolt Biotherapeutics
BOLT
70 hedge funds and large institutions have $1.04B invested in Bolt Biotherapeutics in 2021 Q1 according to their latest regulatory filings, with 70 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.56% more ownership
Funds ownership: 0% → 4.56% (+4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$147M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$126M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$95.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$93.6M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$89.6M |
Top Sellers
BOLT Hedge Fund Activity: Q1 2021 in Review
70 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q1 2021, worth a combined $1.04B.
Buyers outnumbered sellers: 70 funds opened new BOLT positions and 0 closed out — a net gain of 70 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $147M.
- 70 institutional investors held Bolt Biotherapeutics (BOLT) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $1.04B of Bolt Biotherapeutics stock for Q1 2021.
- 70 funds opened new Bolt Biotherapeutics positions in Q1 2021 and 0 closed out, a net change of +70 holders.
- The largest Bolt Biotherapeutics buyer in Q1 2021 was Novo Holdings A/S, an estimated $147M added.
Based on aggregated 13F filings for Q1 2021.